Building a CAR T-Cell Therapy Manufacturing Facility

This case study details the establishment of the largest CAR T-cell therapy manufacturing facility in South Korea by Curocell, a biotechnology company specializing in CAR T-cell therapy. The document outlines the challenges faced in building a Good Manufacturing Practice (GMP) compliant facility, which included adhering to strict regulatory guidelines and ensuring operational efficiency. The facility aims to provide contract manufacturing services and includes an R&D center for further development of cell therapies. The case study describes the solution implemented, which involved partnering with an experienced organization to assist in the setup of the GMP facility. This partnership facilitated the preparation of necessary documentation for GMP validation and provided procedural guidelines and training for operational staff. The impact of this initiative resulted in a significant increase in manufacturing throughput, achieving over a 500% increase, and establishing the facility as the largest CAR T-cell therapy manufacturing site in South Korea, thus supporting Curocell's global business expansion.